PatternsRadar
Sign in

VENUSREMVenus Remedies Limited

NSEASM Stage IIIBand 5%
1,491.00INR-10.60 (-0.71%)Close · 20 Nov 2026
26 Oct 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹1,993 CrMarket cap
16.4P/E (TTM)
49.6%Delivery

Filings & corporate actions

84 results filed
CSV
Next results · Q3 FY27
Expected 29 Jan 2027 – 14 Feb 2027
Estimate: filed 29–45 days after quarter end, last 5 times
Dividend
₹10.00 per share · last 7 Aug 2026
2026
  • 26 OctresultsResults · Q2 FY27 · consolidated and standalone-5.0%NSE
  • 10 OctshareholdingShareholding · 30 Sept 2026+0.6%NSE
  • 7 AugdividendDividend · ₹10.00 per share-1.4%
  • 20 JulresultsResults · Q1 FY27 · consolidated and standalone+4.8%NSE
  • 17 JulshareholdingShareholding · 30 Jun 2026-1.0%NSE
  • 26 MayresultsResults · Q4 FY26 · consolidated and standalone+5.0%NSE
  • 8 AprshareholdingShareholding · 31 Mar 2026+5.0%NSE
  • 29 JanresultsResults · Q3 FY26 · consolidated and standalone+4.7%NSE
  • 6 JanshareholdingShareholding · 31 Dec 2025-2.3%NSE

Reaction to results · all yearsrose on day 0 in 38 of 79 CSV

QuarterFiledDay 0+5D+20DRel vol
Q2 FY2726 Oct 2026-5.0%-10.0%—2.8×
Q1 FY2720 Jul 2026+4.8%-9.6%+7.4%1.6×
Q4 FY2626 May 2026+5.0%+34.0%+67.7%0.7×
Q3 FY2629 Jan 2026+4.7%-2.9%-12.3%3.4×
Q2 FY2610 Nov 2025+13.2%+18.3%+61.6%29.5×
Q1 FY261 Aug 2025-2.0%-10.6%-11.7%0.6×
Q4 FY2526 May 2025+10.8%+26.5%+17.9%29.2×
Q3 FY254 Feb 2025+20.0%+9.7%+3.2%7.9×
Q2 FY2529 Oct 2024-9.9%-6.5%-10.7%6.6×
Q1 FY2513 Aug 2024-12.1%-9.2%-9.3%2.5×
Q4 FY2430 May 2024+11.5%+11.5%+24.2%19.5×
Q3 FY2414 Feb 2024-10.7%-12.1%-22.8%4.9×
Q2 FY249 Nov 2023+12.2%+19.3%+35.7%11.0×
Q1 FY2414 Aug 2023-2.0%-10.8%-11.8%0.2×
Q4 FY2329 May 2023+20.0%+15.8%+30.5%4.0×
Q3 FY2330 Jan 2023-0.1%-6.9%+3.1%1.1×
Q2 FY2312 Nov 2022-1.6%-6.1%-7.6%1.0×
Q1 FY2330 Jul 2022-0.7%-11.1%-9.6%1.3×
Q4 FY2227 May 2022-8.5%+1.1%-5.1%8.8×
Q3 FY2231 Jan 2022-7.4%-5.5%-16.0%3.5×
Q2 FY2230 Oct 2021+9.0%+1.7%-12.1%1.2×
Q1 FY2212 Aug 2021-5.4%-10.1%-9.9%0.4×
Q4 FY211 Jun 2021-5.0%-1.2%+15.6%4.1×
Q3 FY218 Feb 2021+3.1%+7.7%+27.5%5.8×
Q2 FY217 Nov 2020-0.7%-7.0%-6.5%2.2×
Q1 FY2116 Sept 2020+5.0%+26.0%+9.7%0.8×
Q4 FY2022 Aug 2020-5.0%-15.3%+22.8%0.4×
Q3 FY2013 Feb 2020+10.0%+12.4%+41.3%7.6×
Q2 FY2013 Nov 2019+1.6%-10.7%-10.3%0.1×
Q1 FY2013 Aug 2019+1.1%-6.6%-0.9%0.3×
Q4 FY1931 May 2019-2.3%-7.0%-16.5%0.6×
Q3 FY1928 Feb 2019+2.0%+12.7%+20.9%0.6×
Q2 FY1922 Nov 2018-9.3%-18.3%-28.0%1.0×
Q1 FY1931 Aug 2018+1.1%-1.3%-23.1%0.6×
Q4 FY1822 Jun 2018-0.7%-9.4%-20.3%0.4×
Q3 FY1823 Feb 2018+0.1%-6.1%-12.4%0.5×
Q2 FY1812 Dec 2017-1.7%-1.8%+14.4%0.9×
Q1 FY185 Sept 2017+3.5%-0.4%+1.3%1.3×
Q4 FY1717 Jun 2017+0.4%-3.1%-1.3%0.6×
Q3 FY179 Feb 2017+0.4%+3.6%-1.6%0.5×
Q2 FY179 Nov 2016-0.8%-18.6%-12.1%1.2×
Q1 FY1711 Aug 2016+1.7%+4.4%+17.9%0.9×
Q4 FY1629 May 2016-2.1%+21.2%+12.5%0.9×
Q3 FY1613 Feb 2016+4.9%-1.2%-1.1%0.3×
Q2 FY1619 Nov 2015-1.0%-2.0%+10.8%0.5×
Q1 FY1616 Aug 2015-2.2%-16.7%-15.2%0.5×
Q4 FY155 Jun 2015-2.0%-10.0%-3.0%0.7×
Q3 FY1520 Feb 2015-1.1%-10.6%-36.3%0.5×
Q2 FY1525 Nov 2014-0.9%-4.2%-8.2%1.5×
Q1 FY154 Sept 2014+0.6%+16.3%-7.0%2.4×
Q4 FY1418 Jun 2014-0.7%-7.0%-5.0%0.3×
Q3 FY1425 Feb 2014+0.7%+6.6%+4.3%0.8×
Q2 FY1422 Nov 2013+0.1%-0.3%+16.2%0.4×
Q1 FY146 Aug 2013+5.6%+5.5%+9.4%1.1×
Q4 FY1323 May 2013-6.3%+4.4%-9.2%0.3×
Q3 FY1314 Feb 2013+0.6%+1.2%+0.8%0.4×
Q2 FY135 Nov 2012-0.2%-8.0%+2.3%1.0×
Q1 FY136 Aug 2012-1.2%-3.7%+30.8%0.3×
Q4 FY124 May 2012+2.2%+2.0%+3.4%2.1×
Q3 FY1227 Jan 2012-6.5%+11.0%-0.1%2.7×
Q2 FY121 Nov 2011-3.4%-8.7%-21.9%0.7×
Q1 FY1226 Jul 2011+0.3%-4.6%-15.9%0.7×
Q4 FY1130 Apr 2011-0.9%-7.7%-8.1%0.5×
Q3 FY1128 Jan 2011-2.9%-9.0%-11.1%2.4×
Q2 FY1118 Oct 2010+0.3%-2.5%-6.8%3.4×
Q1 FY1131 Jul 2010-1.2%+0.3%+16.6%0.9×
Q4 FY1026 Apr 2010+2.4%+2.9%-4.5%1.5×
Q3 FY1018 Jan 2010-3.6%-14.0%-17.6%0.4×
Q2 FY1031 Oct 2009-6.7%+0.9%-0.3%0.4×
Q1 FY1030 Jul 2009+1.2%+14.2%+17.1%1.5×
Q4 FY0930 Apr 2009+3.7%+8.2%+40.0%0.3×
Q3 FY0931 Jan 2009-5.8%-3.5%-17.3%0.3×
Q2 FY0930 Oct 2008+15.4%+13.4%+3.8%0.6×
Q1 FY0929 Jul 2008-6.1%+1.8%-3.9%0.9×
Q4 FY0829 Apr 2008+1.7%+5.5%+2.1%2.5×
Q3 FY0828 Jan 2008-4.4%+4.2%+7.3%0.8×
Q2 FY0822 Oct 2007+1.1%+3.2%-0.7%0.5×
Q1 FY0823 Jul 2007+0.5%-4.3%-4.2%1.4×
Q4 FY0725 Apr 2007-4.1%-4.7%-8.0%4.7×
Average+0.4%-0.2%+1.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q2 FY27

Revenue YoY+13.5%
Profit YoY+27.4%
Interest cost YoY-50.0%
Revenue QoQ+22.3%
Profit QoQ+11.7%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+16.7%+16.1%—+8.2%+9.2%—
Profit+134.7%+68.4%—+8.3%+55.3%—

Key data

Open1,474.10
Day range1,474.10 – 1,542.70
52-week range550.00 – 2,044.30
From 52w high-27.1%
RSI (14)50.5
ATR (14)83.25
Volume31.1K
Avg volume (20D)41.8K
Rel volume0.74×
Volatility (1Y)55.3%
Turnover₹4.7Cr
Traded value (NSE)₹4.7Cr
VWAP1,512.90
SMA 50 / 2001,544.01 / 1,335.86
Price band5%

Delivery percentage

Latest · 20 Nov 202649.6%
20-day avg82.5%
1-year avg85.6%
Percentile (own history)45th
Range6.1–100.0%
Sessions3,602

Over the last 20 sessions VENUSREM settled 82.5% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 85.6%, so recent sessions are running 3.0 points lower than usual. The latest session ranks higher than 45% of the 3,602 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

Dividends, deals & holders

Dividend yield0.67%
Dividend, trailing 12M₹10.00
Paid every year for1 yr
Shareholders23.0K · +4.9% QoQ
Net bulk deals, 30D0.00%
Block deals, 30D₹0
Last bulk buy609 days ago

Performance returns

1D1W1M3M6M1Y
Price-0.71%-0.45%+3.43%-15.55%+44.68%+160.73%

Valuation

Market cap₹1,993 Cr
Market cap (NSE)₹1,993 Cr
Free-float cap₹1,161 Cr
P/E (TTM)16.4
P/E (NSE)16.5
EPS (TTM)91.04
P/B2.8
Net margin (TTM)14.5%
Other income / PBT6.7%
ROE18.7%
Debt / equity0.00
Shares outstanding1.34Cr
Listed20 Dec 2006

Ownership

Promoter41.76%
Promoter Δ QoQ0.00 pp
Public58.24%
FII3.14%
DII0.74%
Pledged0.00%

Quarterly results · consolidated

Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue (₹ Cr)180.3259.4178.9218.8
YoY chg+1.9%+33.0%+35.6%+13.5%
Net profit (₹ Cr)25.647.523.025.7
YoY chg+30.5%+126.1%+139.3%+27.4%
Net margin14.2%18.3%12.8%11.7%
EPS19.1435.5317.1819.19

Shareholding over time

By quarter

30 Sept 2026 · promoter 41.76% · public 58.24%
30 Sept 2021: promoter 40.81%31 Dec 2021: promoter 40.81%31 Mar 2022: promoter 40.81%30 Jun 2022: promoter 41.76%30 Sept 2022: promoter 41.76%31 Dec 2022: promoter 41.76%31 Mar 2023: promoter 41.76%30 Jun 2023: promoter 41.76%30 Sept 2023: promoter 41.76%31 Dec 2023: promoter 41.76%31 Mar 2024: promoter 41.76%30 Jun 2024: promoter 41.76%30 Sept 2024: promoter 41.76%31 Dec 2024: promoter 41.76%31 Mar 2025: promoter 41.76%30 Jun 2025: promoter 41.76%30 Sept 2025: promoter 41.76%31 Dec 2025: promoter 41.76%31 Mar 2026: promoter 41.76%30 Jun 2026: promoter 41.76%30 Sept 2026: promoter 41.76%
2021-092026-09
  • Promoter
  • Public and others
Promoter
41.76%
Public
58.24%
Promoter change
0.00 pp
Filed
10 Oct 2026
FII
3.14%
DII
0.74%
Promoter pledged
0.00%

Who the public is

Mutual funds
0.00%

0.00 pp QoQ

Insurance
0.00%

0.00 pp QoQ

FPI
3.14%

+0.22 pp QoQ

Retail ≤ ₹2L
31.87%

+0.55 pp QoQ

HNI > ₹2L
12.15%

-0.85 pp QoQ

NRI
1.71%

+0.11 pp QoQ

Bodies corporate
2.97%

-0.01 pp QoQ

Shareholders
22,968

+4.9% QoQ

Major holders

As of 30 Sept 2026
HolderTypeHolding
Sunev Pharma Solutions Pvt LtdPromoter · Corporate17.21%
PAWAN CHAUDHARYPromoter · Individual12.82%
MANU CHAUDHARYPromoter · Individual11.73%
TIKRI PARTNERS LLPCorporate1.97%
RAJNI TARUN JAINIndividual1.42%
ACADIAN EMERGING MARKETS MICRO-CAP EQUITY MASTER FUNDFPI1.10%
NISARG AJAYKUMAR VAKHARIAIndividual1.05%
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRSOther1.00%
PEEYUSH JAINPromoter · Individual0.00%
AKSHANSH CHAUDHARYPromoter · Individual0.00%

Every promoter-group member, and each public holder above 1%, as filed.

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.

Dividends

since 20 Sept 2012 CSV
Financial yearPaymentsDeclaredAdjusted
FY2026-271₹10.00₹10.00
FY2013-141₹3.00₹3.00
FY2012-131₹3.00₹3.00
Ex-dateRecord dateDeclaredAdjusted
7 Aug 2026—₹10.00₹10.00
23 Sept 2013—₹3.00₹3.00
20 Sept 2012—₹3.00₹3.00

Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.

Price-band hits

Loading…

Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.

Book closures & record dates

Loading…

NSE's corporate-action calendar: who held the stock on the record date, or through the book-closure window, was entitled to the dividend, bonus, split or rights named.

Insider trades

Insiders net, 30d
₹0
Insiders net, 90d
₹0
Promoters net, 90d
₹0
Insider buyers, 90d
0
Last promoter buy
4.5 years ago
Disclosures on record
5
1 open-market of the newest 5
By year
BroadcastPersonSideSharesValuePriceHolding before → afterStakeRegulation
31 May 2022PAWAN CHAUDHARYPromoterBuy1.27L₹2.8Cr217.3115.87L → 17.14L12.82%+0.95 pp7(2)told 31 May 2022

SEBI insider-trading disclosures, equity only. Dated by the day NSE broadcast them; the trade itself is often weeks earlier. The figures count promoters, directors and KMPs buying or selling on the exchange — not ESOPs, gifts, transfers within the promoter group or pledges. Stake is the holding after, as filed; the change beneath it scales that by the share counts before and after. Regulation is the PIT clause cited, and “told” the day the insider informed the company.

How the insider figures are countedPromoters buying in the open market, market-wideEvery stock on this session

Bulk & block deals · 30 May 2025

CSV
12 of 185 deals
By year
DateDealClientQuantityPriceValue
30 May 2025Sell · bulkPRADEEP KUMAR JAIN1.36L422.77₹5.7Cr
21 Mar 2025Sell · bulkMC JAIN INFOSERVICES PRIVATE LIMITED90.0K292.70₹2.6Cr
21 Mar 2025Buy · bulkSAMYAK ENTERPRISES90.0K292.70₹2.6Cr
6 Feb 2025Buy · bulkPARTH INFIN BROKERS PVT LTD1.25L354.83₹4.4Cr
6 Feb 2025Sell · bulkPARTH INFIN BROKERS PVT LTD1.14L353.88₹4.1Cr
6 Feb 2025Buy · bulkCRONY VYAPAR PVT LTD75.2K356.91₹2.7Cr
6 Feb 2025Sell · bulkCRONY VYAPAR PVT LTD50.2K352.60₹1.8Cr
13 Jun 2024Sell · bulkGRAVITON RESEARCH CAPITAL LLP69.0K377.21₹2.6Cr
13 Jun 2024Buy · bulkGRAVITON RESEARCH CAPITAL LLP69.0K376.56₹2.6Cr
24 Jan 2024Sell · bulkBNP PARIBAS ARBITRAGE66.9K380.24₹2.5Cr
24 Jan 2024Buy · bulkSOCIETE GENERALE66.8K380.25₹2.5Cr
10 Nov 2023Sell · bulkGRAVITON RESEARCH CAPITAL LLP1.68L322.43₹5.4Cr

A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.

Every stock on this session →

Takeover-code disclosures

Loading…

Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.

Every stock on this session →

Short selling, lending & margin

Loading…

Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.

Exchange surveillance

20 Nov 2026
  • Long-term ASM · Stage III · since 13 Nov 2026 — Long-term Additional Surveillance Measure: after a sustained unusual move, trades carry a higher margin and, at later stages, settle trade-for-trade.

Price band: 5% · not in the F&O ban.

From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.

Every stock on this session →

Financials · quarterly statement

₹ crore, as filed
By year
 Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27Q2 FY27
Revenue from operations143.4195.2108.6167.5176.9195.0131.9192.8180.3259.4178.9218.8
Other income2.43.91.610.62.06.88.71.72.55.02.60.5
Total income145.8199.1110.2178.0178.9201.7140.6194.5182.8264.4181.5219.3
Total expenses138.0181.6103.4169.0163.9170.7128.0168.0149.3202.8151.4185.8
└ Finance costs0.10.00.00.00.00.00.00.00.00.00.00.0
└ Depreciation6.55.96.06.45.44.76.26.26.66.86.89.5
Profit before tax7.817.56.99.124.931.012.626.533.561.630.033.5
Tax expense0.97.05.65.65.37.13.06.47.914.17.17.8
Net profit6.910.51.23.519.621.09.620.125.647.523.025.7
EPS5.137.860.922.6314.6615.717.1815.0619.1435.5317.1819.19
Net margin4.78%5.38%1.12%2.10%11.08%10.77%7.28%10.44%14.19%18.31%12.84%11.73%
PBT margin5.42%8.95%6.31%5.42%14.07%15.92%9.56%13.74%18.57%23.75%16.80%15.30%
Tax rate11.95%39.85%82.19%61.27%21.22%22.91%23.87%24.01%23.57%22.91%23.54%23.36%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 26 Oct 2026.

Balance sheet & cash flow · half-yearly

₹ crore, as filed
By year

Balance sheet

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Total assets601.1640.4626.8660.5715.7768.1853.7839.6
Current assets323.0373.7359.5391.5451.7485.7395.2362.9
└ Cash & equivalents21.24.549.031.357.522.025.118.1
└ Other bank balances32.563.219.147.122.620.64.53.9
└ Current investments20.13.119.155.884.1193.273.868.1
└ Trade receivables76.773.380.567.7112.296.6103.387.7
└ Inventories119.9159.3121.7120.0100.5106.7129.4132.1
Total equity460.3471.0487.6494.2561.0594.3663.8704.5
└ Attributable to owners460.3471.0487.6494.2561.0594.3663.8704.5
└ Non-controlling interest0.00.0—0.0————
└ Share capital13.413.413.413.413.413.413.413.4
Borrowings42.341.741.340.91.71.30.00.0
└ Current3.63.12.72.21.71.30.00.0
└ Non-current38.738.738.738.70.00.00.00.0
Trade payables50.856.044.263.491.997.9113.553.2
Current liabilities82.6109.979.4101.0136.3143.1161.8109.6
Total liabilities140.7169.5139.3166.2154.8173.8190.0135.1
Net debt(31.6)(29.0)(45.9)(93.3)(162.5)(234.4)(103.4)(90.2)
Debt / equity0.090.090.080.080.000.000.000.00
Current ratio3.913.404.533.873.313.402.443.31

Cash flow, year to date

 FY23H1 FY24FY24H1 FY25FY25H1 FY26FY26H1 FY27
Operating cash flow36.6(2.5)37.325.686.581.1155.826.3
└ Capex(7.8)(3.9)(13.5)(11.5)(18.1)(26.2)(37.7)(25.9)
Free cash flow28.8(6.4)23.814.168.454.9118.10.4
Investing cash flow(50.8)17.0(7.2)(41.8)(76.3)(126.9)(181.6)(18.7)
Financing cash flow(0.6)(0.6)(1.1)(0.5)(1.0)12.7(3.1)(14.6)
└ Dividends paid0.00.00.00.00.00.00.0(13.4)
└ Buybacks0.00.00.00.00.00.00.00.0
Net change in cash(14.8)14.027.7(16.7)9.2(33.1)(28.9)(7.0)

From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.

Announcements & board meetings

Loading…

As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.

Every stock on this session →

VENUSREM at a glance

  • VENUSREM closed at ₹1,491 on 20 Nov 2026, -0.71% on the day, +160.7% over one year, 27.1% below its 52-week high of ₹2,044.3.
  • Delivery was 49.6% of traded quantity on 20 Nov 2026, the 45th percentile of its own 3,602 sessions with a reading (20-session average 82.5%, 1-year average 85.6%).
  • Market capitalisation is ₹1,993 crore at a trailing P/E of 16.4 (trailing EPS ₹91.04).
  • Q2 FY27 results (consolidated, filed 26 Oct 2026): revenue ₹219 crore (+13.5% year on year), net profit ₹26 crore (+27.4%); the price moved -5.0% on the first session after.
  • Promoters held 41.76% at 30 Sept 2026, unchanged on the previous filing.
  • Q3 FY27 results are expected between 29 Jan 2027 and 14 Feb 2027, going by past filing dates — an estimate, not an announcement.

About

Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE411B01019
SeriesEQ
Listed20 Dec 2006
NSE market cap · 17 Nov 2026₹2,039 Cr
Free-float market cap (NSE)₹1,167 Cr
Shares outstanding (NSE)1.34Cr
History from20 Dec 2006
Sessions4,924

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.